Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Table 3 Summary of clinical characteristics of patients without del[5q] on MC who received lenalidomide (N = 42)

Diagnosis (No. of Patients)
MDS		31
	RA		5
	RARS		13
	RCMD		1
	RAEB-1		4
	RAEB-2		7
	MDS-U		1
MDS/MPN		7
	CMML-1		2
	CMML-2		2
	MDS/MPN-U		3
PMF		2
sAML		2
Age (years old)
	Median (Range)		70 (46-83)
Sex (No. of Patients)
	M		28
	F		14
IPSS (No. of Patients)
	LOW		12
	INT-1		11
	INT-2		7
	HIGH		1
	not indicated		11
Duration of MDS (months)
	Median (Range)		15 (0-118)
Previous Therapies
	Yes		27
	No		15
Transfusion dependence (No. of Patients)
	Yes		30
	No		12
Neutropenia (< 1.5 × 10⁹/μ) (No. of Patients)
	Yes		5
	No		37
Thrombocytopenia (< 100 × 10⁹) (No. of Patients)
	Yes		12
	No		30
Therapy (No. of Patients)
LEN (5-10 mg/day) alone			30
LEN high dose (50 mg/day)			1
	LEN/AZA		11
Duration of LEN therapy (months)
	Median (Range)		5 (0-76)
Response to therapy (No. of Patients)
	CR		9
	PR		3
	HI		10
	NR		16
	NE		4

Abbreviation: MDS myelodysplastic syndromes; RA refractory anemia; RARS refractory anemia with ring sideroblasts; RCMD refractory cytopenia with multilineage dysplasia; RAEB refractory anemia with excess blasts, MDS-U MDS unclassifiable; MDS/MPN MDS/myeloproliferative neoplasm; CMML chronic myelomonocytic leukemia; MDS/MPN-U MDS/MPN unclassifiable; PMF primary myelofibrosis; sAML secondary acute myeloid leukemia; M male; F female; LEN lenalidomide; LEN/AZA LEN/azacitidine; CR complete response; PR partial response; HI hematological improvement; NR no response; NE not evaluated.

ISSN: 1756-8722